Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Monday, 5 February 2018

Novo Nordisk A/S - Share repurchase programme

Novo Nordisk A/S    

Published: 20:47 CET 05-02-2018 /GlobeNewswire /Source: Novo Nordisk A/S / : NOVO B /ISIN: DK0060534915

Novo Nordisk A/S - Share repurchase programme

Bagsværd, Denmark, 5 February 2018 - As part of the up to DKK 14 billion 2018 share repurchase programme, Novo Nordisk A/S has now initiated a new share repurchase programme for an amount of up to DKK 2.5 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour Rules.

For that purpose, Novo Nordisk A/S has appointed Nordea Danmark, filial af Nordea Bank AB (publ) as lead manager to execute the programme independently and without influence from Novo Nordisk A/S. The purpose of the programme is to reduce the company's share capital and to meet obligations arising from share-based incentive programmes. Under the agreement, Nordea Danmark, filial af Nordea Bank AB (publ) will repurchase B shares on behalf of Novo Nordisk A/S during the trading period starting 6 February and ending on 30 April 2018. A maximum of 479,456 B shares can be bought during one single trading day, equal to 20% of the average daily trading volume of Novo Nordisk B shares on Nasdaq Copenhagen during the month of January 2018, and a maximum of 26,849,536 B shares in total can be bought during the trading period. At least once every seven trading days, Novo Nordisk A/S will issue an announcement in respect of the transactions made under the repurchase programme.



Further information




Anne Margrethe Hauge

+45 4442 3450


Ken Inchausti (US)

+1 609 786 8316








Peter Hugreffe Ankersen

+45 3075 9085


Hanna Ögren

+45 3079 8519


Anders Mikkelsen

+45 3079 4461


Christina Kjær

+45 3079 3009


Kasper Veje (US)

+1 609 235 8567



Company announcement No 10 / 2018 



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Novo Nordisk A/S, Novo Allé, Bagsvaerd DK-2880, Denmark
If you would like to unsubscribe and stop receiving these e-mails click here.